Menstrual Health

Menstrual Care Company Sunny Earns FDA Clearance for Its Sunny Cup + Applicator

Sunny, a self-care brand in menstrual care, has achieved another milestone with their Sunny Cup + Applicator, now the first menstrual cup and applicator to receive FDA 510(k) clearance. This Class II Medical Device addresses the primary barrier preventing tampon users from switching to more sustainable menstrual products, free from potentially harmful materials. Sunny is a queer, women, and BIPOC-owned self-care brand…

Afynia Laboratories Secures $1.5M to Advance Endometriosis Diagnosis with EndomiR

Afynia Laboratories, a Canada-based startup led by former McMaster University researchers, has raised $1.5 million USD to advance the commercialization of their innovative endometriosis test, EndomiR. Co-founders Lauren Foster and Jocelyn Wessels aim to significantly improve the diagnostic process for endometriosis, a condition affecting millions of women globally. Afynia Laboratories, under the leadership of CEO Lauren Foster and Chief Scientific Officer Jocelyn…

Flo Health Secures Over $200M Series C Investment from General Atlantic, Achieves Unicorn Status

Flo Health, a leading women’s health app, has raised more than $200 million in a Series C investment from General Atlantic, a prominent global growth investor. This investment propels Flo’s valuation beyond $1 billion, making it the first purely digital consumer women’s health app to achieve unicorn status. Flo Health’s mission is to support women at every stage of their health journey,…

UC Berkley Study to Measure Toxic Metals in Tampons Finds Arsenic and Lead Among Contaminants

Tampons from several brands, potentially used by millions of people each month, can contain toxic metals like lead, arsenic, and cadmium, according to a new study led by a UC Berkeley researcher. Tampons are a particular concern as a potential source of chemical exposure because the vaginal skin has a higher potential for chemical absorption than skin elsewhere on the body. Additionally,…

Daye Launches Gynaecological Consultation Service for Faster Healthcare Access

Gynaecological health startup Daye has announced the launch of a comprehensive gynaecological health consultation and pharmacy service. This new service aims to provide women with faster access to healthcare, offering advice, diagnosis, and prescriptions. Specialist nurses, vetted and NHS-trained with over 20 years of experience, will offer in-depth, personalized advice on period pain, vaginal and sexual health, fertility, and menopause. This service…

Women’s Health DTC Platform Unfabled Launches Consumer Insights Platform; Introduces New Range of Signature Supplements

UK-based women’s health and wellbeing platform Unfabled is launching Unfabled Labs, a new consumer insights and research platform aimed at driving innovation in the women’s health and wellbeing industry. The platform will leverage data from over 400,000 women and non-binary individuals to support the development of new products and services tailored to their specific health needs. “Significantly increasing the safe collection of…

TiumBio Shares Positive Phase 2a Trial Results for Merigolix in Endometriosis Treatment Following $12M Funding Round

TiumBio, a clinical-stage biopharmaceutical company based in South Korea, recently unveiled encouraging findings from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, aimed at alleviating moderate to severe endometriosis-associated pain. This announcement comes on the heels of a successful $12 million funding round, earmarked to advance the company’s clinical pipeline. The Phase 2a trial showcased promising…

Samphire Neuroscience Raises $2.3M in Pre-seed Funding for Novel Neurotechnology Wearable Targeting PMS & Menstrual Pain

Samphire Neuroscience, a medtech startup, has announced a successful $2.3 million pre-seed funding round for its pioneering neurotechnology wearable, Nettle. Designed to manage premenstrual syndrome (PMS) and menstrual pain, Nettle represents a significant step forward in at-home neurostimulation treatment. With over 90% of women affected by menstrual pain and PMS at some point, the demand for such solutions is evident. The funding…